GlassScriptPhysician profile
Nam Quoc Bui
NPI 1982994802
$8,120.98
in general payments reported to CMS, 2019-2025
6 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $76.23 · 2023: $39.70 · 2024: $6,651 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,720 · Consulting Fee: $2,610 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,200 · Food and Beverage: $480 · Travel and Lodging: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,720.00 |
| Consulting Fee | $2,610.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,200.00 |
| Food and Beverage | $479.75 |
| Travel and Lodging | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $3,285.77 | 2024-2025 | Vimseltinib, Romvimza, Qinlock |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,610.00 | 2024 | |
| Aadi Bioscience, INC. | $2,055.00 | 2024 | |
| Daiichi Sankyo INC. | $130.51 | 2022-2024 | Turalio |
| Pfizer INC. | $39.70 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nam Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.